logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9512111 B1

PDFFull Text
Date of Patent:
Dec. 06, 2016

Filed:

Nov. 08, 2011

N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of rorγ activity and the treatment of disease

Applicants:

Gary D. Glick, Ann Arbor, MI (US);

Peter L. Toogood, Ann Arbor, MI (US);

Arthur G. Romero, Chesterfield, MO (US);

Chad A. Van Huis, Hartland, MI (US);

Thomas D. Aicher, Ann Arbor, MI (US);

Carl Kaub, San Mateo, CA (US);

Matthew N. Mattson, Santa Clara, CA (US);

William D. Thomas, San Jose, CA (US);

Karin A. Stein, Mountain View, CA (US);

Erik Krogh-jespersen, Palo Alto, CA (US);

Zhan Wang, San Jose, CA (US);

Inventors:

Gary D. Glick, Ann Arbor, MI (US);

Peter L. Toogood, Ann Arbor, MI (US);

Arthur G. Romero, Chesterfield, MO (US);

Chad A. Van Huis, Hartland, MI (US);

Thomas D. Aicher, Ann Arbor, MI (US);

Carl Kaub, San Mateo, CA (US);

Matthew N. Mattson, Santa Clara, CA (US);

William D. Thomas, San Jose, CA (US);

Karin A. Stein, Mountain View, CA (US);

Erik Krogh-Jespersen, Palo Alto, CA (US);

Zhan Wang, San Jose, CA (US);

Assignee:

Lycera Corporation, Ann Arbor, MI (US);

Attorney:

Goodwin Procter LLP

Primary Examiner:

Sarah Pihonak

Int. Cl.
CPC ...
C07D 413/06 (2006.01); C07D 209/08 (2006.01); C07D 209/34 (2006.01); C07D 215/58 (2006.01); C07D 231/56 (2006.01); C07D 241/50 (2006.01); C07D 265/36 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 409/12 (2006.01); C07D 413/04 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
C07D 413/06 (2013.01); C07D 209/08 (2013.01); C07D 209/34 (2013.01); C07D 215/58 (2013.01); C07D 231/56 (2013.01); C07D 241/50 (2013.01); C07D 265/36 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 409/12 (2013.01); C07D 413/04 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01);
Abstract

The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting RORγ activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.

Find Patent Forward Citations

Loading…